Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Continued Understanding of Bevacizumab
Donald M. McDonald, MD, PhD
Advertisement
Articles by Donald M. McDonald, MD, PhD
Dr. Donald McDonald from UCSF Comprehensive Cancer Center Explains Approved Angiogenesis Inhibitors
Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Next Step for Angiogenesis Inhibitors
Dr. Donald M. McDonald from the UCSF Cancer Center Discusses Resistance to Angiogenesis Inhibitors
Advertisement
Latest Updated Articles
Dr. McDonald on Approved Angiogenesis InhibitorsSeptember 22nd 2011
Dr. McDonald on the Continued Understanding of BevacizumabOctober 6th 2011
Dr. McDonald on Resistance to Angiogenesis InhibitorsSeptember 8th 2011
Dr. McDonald on the Next Step for Angiogenesis InhibitorsSeptember 13th 2011
Advertisement
Advertisement
Trending on OncLive
1
Venetoclax/Ibrutinib Clears Resistance Mutations in BTK Inhibitor–Resistant CLL
2
Sacituzumab Govitecan Approved in Europe for First-Line PD-L1 Inhibitor–Ineligible TNBC
3
Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC
4
NCCN Includes PCR ctDNA-MRD Testing in MIBC Treatment Algorithm
5